TAR-200 eliminated tumors in 82% of patients in a phase 2 trial for patients with high-risk non-muscle-invasive bladder ...

The FDA has approved Inlexzo for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday’s episode of her podcast, “Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is ...

The indication for the chemotherapy-containing system stipulates use in adults with bacillus Calmette-Guerin ...

The FDA has approved a gemcitabine intravesical system for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive ...

Sensome, the pioneer of microsensing technology for real-time, intra-operative tissue analysis, announced today it has completed enrollment in the first-in-human INSPECT study of its novel technology, ...

This new article publication from Acta Pharmaceutica Sinica B, discusses the use of in situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and ...

Approval was based on data from the Phase IIb SunRISe-1 trial (NCT04640623), in which Inlexzo demonstrated an 82% complete ...

Stage 0 cancer, or carcinoma in situ, is the earliest form of cancer where abnormal cells remain localized. Experts stress ...